Release Summary

European Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA for the First-Line Treatment of Patients with Metastatic NSCLC Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations

Merck